Using a Rasch Model to Rank Big Pharmaceutical Firms by Financial Performance.
- Published in:
- Journal of Commercial Biotechnology, 2016, v. 22, n. 1, p. 49, doi. 10.5912/jcb734
- By:
- Publication type:
- Article
Works matching IS 14628732 AND DT 2016 AND VI 22 AND IP 1
Results: 8
1
2
An Impediment to Personalized Medicine Commercialization is the Lack of Understanding of the Value of the Testing.
- Published in:
- Journal of Commercial Biotechnology, 2016, v. 22, n. 1, p. 3, doi. 10.5912/jcb732
- By:
- Publication type:
- Article
3
Intellectual Property Protection for Biologics: Why the Trans-Pacific Partnership (TPP) Trade Agreement Fails to Deliver<sub>i</sub>.
- Published in:
- Journal of Commercial Biotechnology, 2016, v. 22, n. 1, p. 42, doi. 10.5912/jcb731
- By:
- Publication type:
- Article
4
Moving from preclinical research to development.
- Published in:
- 2016
- By:
- Publication type:
- Proceeding
5
Encouraging Innovation in Preventive Health Technology: A Spotlight on Women's Health.
- Published in:
- Journal of Commercial Biotechnology, 2016, v. 22, n. 1, p. 31, doi. 10.5912/jcb727
- By:
- Publication type:
- Article
6
VC-backed Biotechnology Firms: What is Entrepreneurs' Return?
- Published in:
- Journal of Commercial Biotechnology, 2016, v. 22, n. 1, p. 23, doi. 10.5912/jcb722
- By:
- Publication type:
- Article
7
Marketing authorization of medical devices in China.
- Published in:
- Journal of Commercial Biotechnology, 2016, v. 22, n. 1, p. 15, doi. 10.5912/jcb720
- By:
- Publication type:
- Article
8
Biopharmaceutical Startup's Need of Regulatory Intelligence.
- Published in:
- Journal of Commercial Biotechnology, 2016, v. 22, n. 1, p. 6, doi. 10.5912/jcb675
- By:
- Publication type:
- Article